An Open-Label Study of Apabetalone in Covid Infection
An Open-Label Study to Assess the Safety and Effect on Clinical Course and Key Biomarkers of Oral Apabetalone in Hospitalized Subjects With Covid-19 Infection in Addition to Standard of Care (SOC)
Sponsor: Resverlogix Corp
Terminated
Unable to recruit subjects
Other terminated trials from Resverlogix Corp
More terminations from Resverlogix Corp
This PHASE2/PHASE3 trial investigates COVID-19 Infection and is currently terminated or withdrawn. Resverlogix Corp leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
Status: Unknown Status → Terminated
-
Jun 2023 — Dec 2023 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
Feb 2022 — Jun 2023 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 2 earlier versions
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Resverlogix Corp
For direct contact, visit the study record on ClinicalTrials.gov .